Skip to main content
. 2021 Feb 3;5(2):e528. doi: 10.1097/HS9.0000000000000528

Figure 1.

Figure 1.

Recommendations for MM front-line therapy. ASCT = autologous stem cell transplantation; DaraRd = daratumumab/lenalidomide/dexamethasone; DaraVMP = daratumumab/bortezomib/melphalan/prednisone; DaraVTD = daratumumab/bortezomib/thalidomide/dexamethasone; MM = multiple myeloma; Rd = lenalidomide/dexamethasone; VCD = bortezomib/cyclophosphamide/dexamethasone; VMP = bortezomib/melphalan/prednisone; VRd = bortezomib/lenalidomide/dexamethasone; VTD = bortezomib/thalidomide/dexamethasone.